

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Credelio 56 mg chewable tablets for dogs (1.3-2.5 kg)
Credelio 112 mg chewable tablets for dogs (>2.5-5.5 kg)
Credelio 225 mg chewable tablets for dogs (>5.5-11 kg)
Credelio 450 mg chewable tablets for dogs (>11-22 kg)
Credelio 900 mg chewable tablets for dogs (>22-45 kg)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:

Each chewable tablet contains:

Credelio chewable tablets	lotilaner (mg)
for dogs (1.3-2.5 kg)	56.25
for dogs (>2.5-5.5 kg)	112.5
for dogs (>5.5-11 kg)	225
for dogs (>11-22 kg)	450
for dogs (>22-45 kg)	900

Excipients:

Qualitative composition of excipients and other constituents
Cellulose, powdered
Lactose monohydrate
Silicified microcrystalline cellulose
Meat dry flavour
Crospovidone
Povidone K30
Sodium laurilsulfate
Silica, colloidal anhydrous
Magnesium stearate

White to beige round chewable tablets with brownish spots.

3. CLINICAL INFORMATION

3.1 Target species

Dogs

3.2 Indications for use for each target species

For the treatment of flea and tick infestations in dogs.

This veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas (*Ctenocephalides felis* and *C. canis*) and ticks (*Rhipicephalus sanguineus*, *Ixodes ricinus*, *I. hexagonus* and *Dermacentor reticulatus*).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

For reduction of the risk of infection with *Babesia canis canis* via transmission by *Demacantor reticulatus* for one month. The effect is indirect due to the activity of the veterinary medicinal product against the vector.

For the treatment of demodicosis (caused by *Demodex canis*).

For the treatment of sarcoptic mange (*Sarcoptes scabiei* var. *canis*).

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

Parasites need to start feeding on the host to become exposed to lotilaner; therefore, the risk of the transmission of parasite borne diseases cannot be completely excluded. Specifically, as an acaricidal effect against *D. reticulatus* may take up to 48 hours, transmission of *B. canis canis* during the first 48 hours cannot be excluded.

3.5 Special precautions for use

Special precautions for safe use in the target species:

All safety and efficacy data have been acquired from dogs and puppies 8 weeks of age and older and 1.3 kg of body weight and greater. Use of this veterinary medicinal product in puppies younger than 8 weeks of age or less than 1.3 kg of body weight should be based on a benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after handling the product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Diarrhoea ^{1,2} , Bloody diarrhoea ¹ , Vomiting ^{1,2} ; Anorexia ^{1,2} , Lethargy ² , Polydipsia ^{1,2} ; Ataxia ³ , Convulsion ³ , Tremor ³ ; Pruritus ^{1,2} ; Inappropriate urination ¹ , Polyuria ^{1,2} , Urinary incontinence ^{1,2}
-----------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

¹ Mild and transient

² Typically resolve without treatment

³ Transient in most cases

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy, lactation or in breeding dogs.

Pregnancy and lactation:

Use only according to the benefit/risk assessment by the responsible veterinarian.

Laboratory studies in rats have not produced any evidence of teratogenic effects or any adverse effect on the reproductive capacity of males and females.

3.8 Interaction with other medicinal products and other forms of interaction

None known.

During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed.

3.9 Administration routes and dosage

For oral use.

The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 20 to 43 mg lotilaner/kg bodyweight.

Body weight of dog (kg)	Strength and number of tablets to be administered				
	Credelio 56 mg	Credelio 112 mg	Credelio 225 mg	Credelio 450 mg	Credelio 900 mg
1.3-2.5	1				
>2.5-5.5		1			
>5.5-11.0			1		
>11.0-22.0				1	
>22.0-45.0					1
>45	Appropriate combination of tablets				

Use an appropriate combination of available strengths to achieve the recommended dose of 20-43 mg/kg.

Credelio is a palatable chewable flavoured tablet. Administer the chewable tablet(s) monthly with or after food.

For the treatment of demodicosis (caused by *Demodex canis*):

Monthly administration of the product for two consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until two negative skin scrapings are obtained one month apart. Severe cases may require prolonged monthly treatments. As demodicosis is

a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

For the treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*):
Monthly administration of the product for two consecutive months. Further monthly administration of the product may be required based on clinical assessment and skin scrapings.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No adverse reactions were observed following oral administration to puppies aged 8-9 weeks and weighing 1.3-3.6 kg treated with overdoses of up to 5 times the maximum recommended dose (43 mg, 129 mg and 215 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code :

QP53BE04

4.2 Pharmacodynamics

Lotilaner, a pure enantiomer from the isoxazoline class is active against fleas (*Ctenocephalides felis* and *Ctenocephalides canis*), - the tick species *Dermacentor reticulatus*, *Ixodes hexagonus*, *Ixodes ricinus* and *Rhipicephalus sanguineus* as well as *Demodex canis* and *Sarcoptes scabiei* var. *canis* mites.

Lotilaner is a potent inhibitor of gamma-aminobutyric acid (GABA)-gated chloride channels, resulting in rapid death of ticks and fleas. The activity of lotilaner was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin).

For fleas, the onset of efficacy is within 4 hours of attachment for one month after product administration. Fleas on the animal prior to administration are killed within 6 hours.
For ticks, the onset of efficacy is within 48 hours of attachment for one month after product administration. Existing *I. ricinus* ticks on the animal prior to administration are killed within 8 hours.

The veterinary medicinal product kills existing and newly emerged fleas on dogs before they can lay eggs. Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the dog has access.

4.3 Pharmacokinetics

Following oral administration, lotilaner is readily absorbed and peak blood concentration is reached within 2 hours. Food enhances the absorption. The terminal half-life is approximately 4 weeks. This long terminal half-life provides effective blood concentrations for the entire duration of the inter-dosing interval.

The major route of elimination is biliary excretion and renal excretion is the minor route of elimination (less than 10% of the dose). Lotilaner is metabolized to a small extent into more hydrophilic compounds which are observed in faeces and urine.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

The tablets are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. Each tablet strength is available in pack sizes of 1, 3, 6 or 18 tablets.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Elanco GmbH

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/17/206/001-015

EU/2/17/206/024-028

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 25/04/2017

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{DD/MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Credelio 12 mg chewable tablets for cats (0.5-2.0 kg)
Credelio 48 mg chewable tablets for cats (>2.0-8.0 kg)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:

Each chewable tablet contains:

Credelio chewable tablets	lotilaner (mg)
for cats (0.5-2.0 kg)	12
for cats (>2.0-8.0 kg)	48

Excipients:

Qualitative composition of excipients and other constituents
Yeast powder (flavour)
Silicified microcrystalline cellulose
Cellulose, powdered
Lactose monohydrate
Povidone K30
Crospovidone
Sodium laurilsulfate
Vanillin (flavour)
Silica, colloidal anhydrous
Magnesium stearate

White to brownish round chewable tablets with brownish spots.

3. CLINICAL INFORMATION

3.1 Target species

Cats

3.2 Indications for use for each target species

For the treatment of flea and tick infestations on cats.

This veterinary medicinal product provides immediate and persistent killing activity for 1 month against fleas (*Ctenocephalides felis* and *C. canis*) and ticks (*Ixodes ricinus*).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

Parasites need to start feeding on the host to become exposed to lotilaner; therefore, the risk of the transmission of parasite borne diseases cannot be completely excluded.

Acceptable levels of efficacy may not be achieved if the veterinary medicinal product is not administered with food or within 30 minutes after feeding.

Due to insufficient data to support efficacy against ticks in young cats, this product is not recommended for the treatment of ticks in kittens 5 months of age or younger.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Safety and efficacy data has been studied in cats aged 8 weeks and older with a body weight of 0.5 kg or more. Therefore, use of this veterinary medicinal product in kittens younger than 8 weeks of age or less than 0.5 kg of body weight should be based on a benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after handling the product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Cats:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Hyperactivity ^{1,2} Vomiting ² Ataxia, Muscle tremor Tachypnoea Pruritus ^{1,2} Anorexia, Lethargy
-----------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------

¹ Mild and transient

² Typically resolves without treatment

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy or lactation.

Pregnancy and lactation:

Use only according to the benefit/risk assessment by the responsible veterinarian.

Laboratory studies in rats have not produced any evidence of teratogenic effects, or any adverse effect on the reproductive capacity of males and females.

3.8 Interaction with other medicinal products and other forms of interaction

None known.

During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed.

3.9 Administration routes and dosage

For oral use.

The flavoured veterinary medicinal product should be administered in accordance with the following table to ensure a single dose of 6 to 24 mg lotilaner/kg bodyweight.

Body weight of cat (kg)	Strength and number of tablets to be administered	
	Credelio 12 mg	Credelio 48 mg
0.5-2.0	1	
>2.0-8.0		1
>8.0	Appropriate combination of tablets	

For cats of more than 8 kg body weight, use an appropriate combination of available strengths to achieve the recommended dose of 6–24 mg/kg.

Administer the veterinary medicinal product with food or within 30 minutes after feeding.

For optimal control of tick and flea infestations, the veterinary medicinal product should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No adverse reactions were observed following oral administration to kittens aged 8 weeks, weighing 0.5 kg, which were treated with more than 5 times the maximum recommended dose (130 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code : QP53BE04

4.2 Pharmacodynamics

Lotilaner, a pure enantiomer from the isoxazoline class, is active against fleas (*Ctenocephalides felis* and *Ctenocephalides canis*) and ticks (*Ixodes ricinus*).

Lotilaner is a potent inhibitor of gamma-aminobutyric acid (GABA)-gated chloride channels, resulting in rapid death of ticks and fleas. In *in vitro* studies, the activity of lotilaner against some arthropod species was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin).

For fleas, the onset of efficacy is within 12 hours of attachment for one month after product administration. Fleas on the animal prior to administration are killed within 8 hours. For ticks, the onset of efficacy is within 24 hours of attachment for one month after product administration. Existing ticks on the animal prior to administration are killed within 18 hours.

The-veterinary medicinal product kills existing and newly emerged fleas on cats before they can lay eggs. Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the cat has access.

4.3 Pharmacokinetics

Following oral administration, lotilaner is readily absorbed and peak blood concentration is reached at 4 hours. Lotilaner is approximately 10 times more bioavailable when administered with food. The terminal half-life is approximately 4 weeks (harmonic mean). This terminal half-life provides effective blood concentrations for the entire duration of the inter-dosing interval.

The major route of elimination is biliary excretion, and renal excretion is the minor route of elimination (less than 10 % of the dose). Lotilaner is metabolized to a small extent into more hydrophilic compounds, which are observed in faeces and urine.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

The tablets are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. Each tablet strength is available in pack sizes of 1, 3, 6 or 18 tablets.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Elanco GmbH

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/17/206/016-023

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 25/04/2017

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{DD/MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARDBOARD BOX (DOGS)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Credelio 56 mg chewable tablets for dogs (1.3-2.5 kg)
Credelio 112 mg chewable tablets for dogs (>2.5-5.5 kg)
Credelio 225 mg chewable tablets for dogs (>5.5-11 kg)
Credelio 450 mg chewable tablets for dogs (>11-22 kg)
Credelio 900 mg chewable tablets for dogs (>22-45 kg)

2. STATEMENT OF ACTIVE SUBSTANCES

56 mg lotilaner
112 mg lotilaner
225 mg lotilaner
450 mg lotilaner
900 mg lotilaner

3. PACKAGE SIZE

1 tablet
3 tablets
6 tablets
18 tablets

4. TARGET SPECIES

Dogs

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.
Administer with or after food.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Elanco GmbH

14. MARKETING AUTHORISATION NUMBERS

EU/2/17/206/001 (56 mg lotilaner; 1 chewable tablet)
EU/2/17/206/002 (56 mg lotilaner; 3 chewable tablets)
EU/2/17/206/003 (56 mg lotilaner; 6 chewable tablets)
EU/2/17/206/024 (56 mg lotilaner; 18 chewable tablets)
EU/2/17/206/004 (112 mg lotilaner; 1 chewable tablet)
EU/2/17/206/005 (112 mg lotilaner; 3 chewable tablets)
EU/2/17/206/006 (112 mg lotilaner; 6 chewable tablets)
EU/2/17/206/025 (112 mg lotilaner; 18 chewable tablets)
EU/2/17/206/007 (225 mg lotilaner; 1 chewable tablet)
EU/2/17/206/008 (225 mg lotilaner; 3 chewable tablets)
EU/2/17/206/009 (225 mg lotilaner; 6 chewable tablets)
EU/2/17/206/026 (225 mg lotilaner; 18 chewable tablets)
EU/2/17/206/010 (450 mg lotilaner; 1 chewable tablet)
EU/2/17/206/011 (450 mg lotilaner; 3 chewable tablets)
EU/2/17/206/012 (450 mg lotilaner; 6 chewable tablets)
EU/2/17/206/027 (450 mg lotilaner; 18 chewable tablets)
EU/2/17/206/013 (900 mg lotilaner; 1 chewable tablet)
EU/2/17/206/014 (900 mg lotilaner; 3 chewable tablets)
EU/2/17/206/015 (900 mg lotilaner; 6 chewable tablets)
EU/2/17/206/028 (900 mg lotilaner; 18 chewable tablets)

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARDBOARD BOX (CATS)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Credelio 12 mg chewable tablets for cats (0.5-2.0 kg)
Credelio 48 mg chewable tablets for cats (>2.0-8.0 kg)

2. STATEMENT OF ACTIVE SUBSTANCES

12 mg lotilaner
48 mg lotilaner

3. PACKAGE SIZE

1 tablet
3 tablets
6 tablets
18 tablets

4. TARGET SPECIES

Cats

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.
Administer with food or within 30 minutes after feeding.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Elanco GmbH

14. MARKETING AUTHORISATION NUMBERS

EU/2/17/206/016 (12 mg lotilaner; 1 chewable tablet)
EU/2/17/206/017 (12 mg lotilaner; 3 chewable tablets)
EU/2/17/206/018 (12 mg lotilaner; 6 chewable tablets)
EU/2/17/206/022 (12 mg lotilaner; 18 chewable tablets)
EU/2/17/206/019 (48 mg lotilaner; 1 chewable tablet)
EU/2/17/206/020 (48 mg lotilaner; 3 chewable tablets)
EU/2/17/206/021 (48 mg lotilaner; 6 chewable tablets)
EU/2/17/206/023 (48 mg lotilaner; 18 chewable tablets)

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
BLISTERS (DOGS)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Credelio



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

56 mg lotilaner
112 mg lotilaner
225 mg lotilaner
450 mg lotilaner
900 mg lotilaner

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
BLISTERS (CATS)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Credelio



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

12 mg lotilaner
48 mg lotilaner

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Credelio 56 mg chewable tablets for dogs (1.3-2.5 kg)
Credelio 112 mg chewable tablets for dogs (>2.5-5.5 kg)
Credelio 225 mg chewable tablets for dogs (>5.5-11 kg)
Credelio 450 mg chewable tablets for dogs (>11-22 kg)
Credelio 900 mg chewable tablets for dogs (>22-45 kg)

2. Composition

Each chewable tablet contains:

Credelio chewable tablets	lotilaner (mg)
for dogs (1.3-2.5 kg)	56.25
for dogs (>2.5-5.5 kg)	112.5
for dogs (>5.5-11 kg)	225
for dogs (>11-22 kg)	450
for dogs (>22-45 kg)	900

White to beige round chewable tablets with brownish spots.

3. Target species

Dogs



4. Indications for use

Treatment of flea and tick infestations in dogs.

This veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas (*Ctenocephalides felis* and *C. canis*) and ticks (*Rhipicephalus sanguineus*, *Ixodes ricinus*, *I. hexagonus*, and *Dermacentor reticulatus*).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

For reduction of the risk of infection with *Babesia canis canis* via transmission by *Dermacentor reticulatus* for one month. The effect is indirect due to the activity of the veterinary medicinal product against the vector.

For the treatment of demodicosis (caused by *Demodex canis*).

For the treatment of sarcoptic mange (*Sarcoptes scabiei* var. *canis*).

5. Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special warnings:

Parasites need to start feeding on the host to become exposed to lotilaner; therefore, the risk of the transmission of parasite borne diseases cannot be completely excluded. Specifically, as an acaricidal effect against *D. reticulatus* may take up to 48 hours, transmission of *B. canis canis* during the first 48 hours cannot be excluded.

Special precautions for safe use in the target species:

All safety and efficacy data have been acquired from dogs and puppies 8 weeks of age and older and 1.3 kg of body weight and greater. The administration of this product in puppies younger than 8 weeks of age or less than 1.3 kg of body weight should be based on a benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after handling the product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Pregnancy and lactation:

Laboratory studies in rats have not produced any evidence of teratogenic effects.

The safety of the veterinary medicinal product has not been established during pregnancy or lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

Fertility:

Laboratory studies in rats have not produced any evidence of any adverse effect on the reproductive capacity of males and females.

The safety of the veterinary medicinal product has not been established in breeding dogs. Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

None known. During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed.

Overdose:

No adverse reactions were observed following oral administration to puppies aged 8-9 weeks and weighing 1.3-3.6 kg treated with overdoses of up to 5 times the maximum recommended dose (43 mg, 129 mg and 215 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals.

7. Adverse events

Dogs:

<i>Very rare (<1 animal / 10 000 animals treated, including isolated reports):</i>

Diarrhoea ^{1,2} , Bloody diarrhoea ¹ , Vomiting ^{1,2} ;

Anorexia^{1,2}, Lethargy², Polydipsia (increased thirst)^{1,2};
 Ataxia³, Convulsion³, Tremor³;
 Pruritus (itching)^{1,2};
 Inappropriate urination¹, Polyuria (increased urination)^{1,2}, Urinary incontinence^{1,2}

¹ Mild and transient

² Typically resolve without treatment

³ Transient in most cases

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

For oral use.

The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 20 to 43 mg lotilaner/kg bodyweight.

Body weight of dog (kg)	Strength and number of tablets to be administered				
	Credelio 56 mg	Credelio 112 mg	Credelio 225 mg	Credelio 450 mg	Credelio 900 mg
1.3-2.5	1				
>2.5-5.5		1			
>5.5-11.0			1		
>11.0-22.0				1	
>22.0-45.0					1
>45	Appropriate combination of tablets				

Use an appropriate combination of available strengths to achieve the recommended dose of 20-43 mg/kg.

For the treatment of demodicosis (caused by *Demodex canis*):

Monthly administration of the product for two consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until two negative skin scrapings are obtained one month apart. Severe cases may require prolonged monthly treatments. As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

For the treatment of sarcoptic mange (caused by *Sarcoptes scabiei* var. *canis*):

Monthly administration of the product for two consecutive months. Further monthly administration of the product may be required based on clinical assessment and skin scrapings.

9. Advice on correct administration

Credelio is a palatable chewable flavoured tablet. Administer the chewable tablet(s) monthly with or after food.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/17/206/001-015

EU/2/17/206/024-028

The tablets are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. Each tablet strength is available in pack sizes of 1, 3, 6 or 18 tablets.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse events:

Elanco GmbH, Heinz-Lohmann-Str. 4, 27472 Cuxhaven, Germany

België/Belgique/Belgien
Tél/Tel: +32 33000338

Lietuva
Tel: +372 8840389

PV.BEL@elancoah.com

Република България

Тел: +48 221047815

PV.BGR@elancoah.com

Česká republika

Tel: +420 228880231

PV.CZE@elancoah.com

Danmark

Tlf: +45 78775477

PV.DNK@elancoah.com

Deutschland

Tel: +49 32221852372

PV.DEU@elancoah.com

Eesti

Tel: +372 8807513

PV.EST@elancoah.com

Ελλάδα

Τηλ: +386 82880137

PV.GRC@elancoah.com

España

Tel: +34 518890402

PV.ESP@elancoah.com

France

Tél: +33 975180507

PV.FRA@elancoah.com

Hrvatska

Tel: +36 18088411

PV.HRV@elancoah.com

Ireland

Tel: +44 3308221732

PV.IRL@elancoah.com

Ísland

Sími: +45 89875379

PV.ISL@elancoah.com

Italia

Tel: +39 0282944231

PV.ITA@elancoah.com

Κύπρος

Τηλ: +386 82880096

PV.CYP@elancoah.com

Latvija

Tel: +372 8840390

PV.LVA@elancoah.com

PV.LTU@elancoah.com

Luxembourg/Luxemburg

Tél/Tel: +352 20881943

PV.LUX@elancoah.com

Magyarország

Tel.: +36 18506968

PV.HUN@elancoah.com

Malta

Tel: +36 18088530

PV.MLT@elancoah.com

Nederland

Tel: +31 852084939

PV.NLD@elancoah.com

Norge

Tlf: +47 81503047

PV.NOR@elancoah.com

Österreich

Tel: +43 720116570

PV.AUT@elancoah.com

Polska

Tel.: +48 221047306

PV.POL@elancoah.com

Portugal

Tel: +351 308801355

PV.PRT@elancoah.com

România

Tel: +40 376300400

PV.ROU@elancoah.com

Slovenija

Tel: +386 82880093

PV.SVN@elancoah.com

Slovenská republika

Tel: +420 228880231

PV.SVK@elancoah.com

Suomi/Finland

Puh/Tel: +358 753252088

PV.FIN@elancoah.com

Sverige

Tel: +46 108989397

PV.SWE@elancoah.com

United Kingdom (Northern Ireland)

Tel: +44 3308221732

PV.XXI@elancoah.com

Manufacturer responsible for batch release:

Elanco France S.A.S., 26 rue de la Chapelle, 68330 Huningue, France

17. Other information

Lotilaner, a pure enantiomer from the isoxazoline class is active against fleas (*Ctenocephalides felis* and *Ctenocephalides canis*), - the tick species *Dermacentor reticulatus*, *Ixodes hexagonus*, *Ixodes ricinus* and *Rhipicephalus sanguineus* as well as *Demodex canis* and *Sarcoptes scabiei* var. *canis* mites.

Lotilaner is a potent inhibitor of gamma-aminobutyric acid (GABA)-gated chloride channels, resulting in rapid death of ticks and fleas. The activity of lotilaner was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin).

For fleas, the onset of efficacy is within 4 hours of attachment for one month after product administration. Fleas on the animal prior to administration are killed within 6 hours.

For ticks, the onset of efficacy is within 48 hours of attachment for one month after product administration. Existing *I. ricinus* ticks on the animal prior to administration are killed within 8 hours.

The veterinary medicinal product kills existing and newly emerged fleas on dogs before they can lay eggs. Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the dog has access.

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Credelio 12 mg chewable tablets for cats (0.5-2.0 kg)
Credelio 48 mg chewable tablets for cats (>2.0-8.0 kg)

2. Composition

Each chewable tablet contains:

Credelio chewable tablets	lotilaner (mg)
for cats (0.5-2.0 kg)	12
for cats (>2.0-8.0 kg)	48

White to brownish round chewable tablets with brownish spots.

3. Target species

Cats



4. Indications for use

For the treatment of flea and tick infestations on cats.

This veterinary medicinal product provides immediate and persistent killing activity for 1 month against fleas (*Ctenocephalides felis* and *C. canis*) and ticks (*Ixodes ricinus*).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

5. Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special warnings:

Parasites need to start feeding on the host to become exposed to lotilaner; therefore, the risk of the transmission of parasite borne diseases cannot be completely excluded.

Acceptable levels of efficacy may not be achieved if the veterinary medicinal product is not administered with food or within 30 minutes after feeding.

Due to insufficient data to support efficacy against ticks in young cats, this product is not recommended for the treatment of ticks in kittens 5 months of age or younger.

Special precautions for safe use in the target species:

All safety and efficacy data have been acquired from cats and kittens 8 weeks of age and older and 0.5 kg of body weight and greater. Use of this veterinary medicinal product in kittens younger than 8 weeks of age or less than 0.5 kg of body weight should be based on a benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after handling the product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Pregnancy and lactation:

Laboratory studies in rats have not produced any evidence of teratogenic effects.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

Fertility:

Laboratory studies in rats have not produced any evidence of any adverse effect on the reproductive capacity of males and females.

The safety of the veterinary medicinal product in breeding queens has not been established. Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

None known. During clinical testing, no interactions between Credelio chewable tablets and routinely used veterinary medicinal products were observed.

Overdose:

No adverse reactions were observed following oral administration to kittens aged 8 weeks and weighing 0.5 kg treated with overdoses of more than 5 times the maximum recommended dose rate (130 mg lotilaner/kg bodyweight) on eight occasions at monthly intervals.

7. Adverse events

Cats:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):

Hyperactivity^{1,2}

Vomiting²

Ataxia (incoordination), Muscle tremor

Tachypnoea (rapid shallow breathing)

Pruritus (itching)^{1,2}

Anorexia (loss of appetite), Lethargy

¹ Mild and transient

² Typically resolves without treatment

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

For oral use.

The flavoured veterinary medicinal product should be administered in accordance with the following table to ensure a single dose of 6 to 24 mg lotilaner/kg bodyweight.

Body weight of cat (kg)	Strength and number of tablets to be administered	
	Credelio 12 mg	Credelio 48 mg
0.5-2.0	1	
>2.0-8.0		1
>8.0	Appropriate combination of tablets	

For cats of more than 8 kg body weight use an appropriate combination of available strengths to achieve the recommended dose of 6-24 mg/kg.

9. Advice on correct administration

Administer the veterinary medicinal product with food or within 30 minutes after feeding.

For optimal control of tick and flea infestations, the veterinary medicinal product should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/17/206/016-023

The tablets are packaged in aluminium/aluminium blisters packaged into an outer cardboard box. Each tablet strength is available in pack sizes of 1, 3, 6 or 18 tablets.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse events:

Elanco GmbH, Heinz-Lohmann-Str. 4, 27472 Cuxhaven, Germany

België/Belgique/Belgien

Tél/Tel: +32 33000338
PV.BEL@elancoah.com

Република България

Тел: +48 221047815
PV.BGR@elancoah.com

Česká republika

Tel: +420 228880231
PV.CZE@elancoah.com

Danmark

Tlf: +45 78775477
PV.DNK@elancoah.com

Deutschland

Tel: +49 32221852372
PV.DEU@elancoah.com

Eesti

Tel: +372 8807513
PV.EST@elancoah.com

Ελλάδα

Τηλ: +386 82880137
PV.GRC@elancoah.com

Lietuva

Tel: +372 8840389
PV.LTU@elancoah.com

Luxembourg/Luxemburg

Tél/Tel: +352 20881943
PV.LUX@elancoah.com

Magyarország

Tel.: +36 18506968
PV.HUN@elancoah.com

Malta

Tel: +36 18088530
PV.MLT@elancoah.com

Nederland

Tel: +31 852084939
PV.NLD@elancoah.com

Norge

Tlf: +47 81503047
PV.NOR@elancoah.com

Österreich

Tel: +43 720116570
PV.AUT@elancoah.com

España

Tel: +34 518890402
PV.ESP@elancoah.com

France

Tél: +33 975180507
PV.FRA@elancoah.com

Hrvatska

Tel: +36 18088411
PV.HRV@elancoah.com

Ireland

Tel: +44 3308221732
PV.IRL@elancoah.com

Ísland

Sími: +45 89875379
PV.ISL@elancoah.com

Italia

Tel: +39 0282944231
PV.ITA@elancoah.com

Κύπρος

Τηλ: +386 82880096
PV.CYP@elancoah.com

Latvija

Tel: +372 8840390
PV.LVA@elancoah.com

Polska

Tel.: +48 221047306
PV.POL@elancoah.com

Portugal

Tel: +351 308801355
PV.PRT@elancoah.com

România

Tel: +40 376300400
PV.ROU@elancoah.com

Slovenija

Tel: +386 82880093
PV.SVN@elancoah.com

Slovenská republika

Tel: +420 228880231
PV.SVK@elancoah.com

Suomi/Finland

Puh/Tel: +358 753252088
PV.FIN@elancoah.com

Sverige

Tel: +46 108989397
PV.SWE@elancoah.com

United Kingdom (Northern Ireland)

Tel: +44 3308221732
PV.XXI@elancoah.com

Manufacturer responsible for batch release:

Elanco France S.A.S., 26 rue de la Chapelle, 68330 Huningue, France

17. Other information

Lotilaner, a pure enantiomer from the isoxazoline class, is active against fleas (*Ctenocephalides felis* and *Ctenocephalides canis*) and ticks (*Ixodes ricinus*).

Lotilaner is a potent inhibitor of gamma-aminobutyric acid (GABA)-gated chloride channels, resulting in rapid death of ticks and fleas. In *in vitro* studies, the activity of lotilaner against some arthropod species was not affected by resistance to organochlorines (cyclodienes, e.g. dieldrin), phenylpyrazoles (e.g. fipronil), neonicotinoids (e.g. imidacloprid), formamidines (e.g. amitraz) and pyrethroids (e.g. cypermethrin).

For fleas, the onset of efficacy is within 12 hours of attachment for one month after product administration. Fleas on the animal prior to administration are killed within 8 hours.

For ticks, the onset of efficacy is within 24 hours of attachment for one month after product administration. Existing ticks on the animal prior to administration are killed within 18 hours.

The veterinary medicinal product kills existing and newly emerged fleas on cats before they can lay

eggs. Therefore, the product breaks the flea life cycle and prevents environmental flea contamination in areas to which the cat has access.